Literature DB >> 10491515

The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue.

X Xie1, O P Clausen, P De Angelis, M Boysen.   

Abstract

BACKGROUND: Bax, Bcl-2, and p53 proteins are involved in the regulation of apoptosis and have been reported to correlate with prognosis in several tumor types.
METHODS: Bax, Bcl-2, p53, and the level of spontaneous apoptosis were evaluated in formalin fixed, paraffin embedded pretreatment specimens from 85 T1-4 squamous cell carcinomas (SCCs) of the tongue by immunohistochemical methods. The percentage of apoptotic cells labeled by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP labeling (TUNEL) method was expressed as an apoptotic index (AI). For Bax and Bcl-2 evaluation, the fraction of tumor cells stained and the staining intensities were given scores that were added together, resulting in a final score. p53 immunostaining was expressed as a percentage of positive cells.
RESULTS: High AI was significantly associated with high Bax expression (P = 0.0122) and highly differentiated tumors (P = 0.0062). No correlation was found between AI and Bcl-2 expression. There was no correlation between p53 positivity and any of the other apoptosis-related parameters. Whereas low AI scores and low Bax expression correlated significantly with poor prognosis (P = 0.0053 and P = 0.0012, respectively), a low Bcl-2 expression was associated with a favorable clinical outcome (P = 0.0262). Patients with a high Bcl-2/Bax expression ratio had a significantly poorer prognosis than those with a low ratio (P < 0.0001). Multivariate analysis revealed that Bax expression, the Bcl-2/Bax expression ratio, and the T and N classifications were significantly independent prognostic variables. The Bcl-2/Bax expression ratio was the strongest independent prognostic parameter.
CONCLUSIONS: AI, individual Bax and Bcl-2 expression, and particularly the Bcl-2/Bax expression ratio have prognostic value in SCC of the tongue. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491515     DOI: 10.1002/(sici)1097-0142(19990915)86:6<913::aid-cncr4>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival.

Authors:  M Re; A Zizzi; L Ferrante; D Stramazzotti; G Goteri; F M Gioacchini; F Olivieri; G Magliulo; C Rubini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-09       Impact factor: 2.503

2.  Apoptosis in primary oral squamous cell carcinomas without lymph node metastases.

Authors:  Zhi Yan; Guomin Wang; Zhiyong Xie; Handong Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.

Authors:  Atsushi Imai; Benjamin D Zeitlin; Fernanda Visioli; Zhihong Dong; Zhaocheng Zhang; Sudha Krishnamurthy; Emily Light; Frank Worden; Shaomeng Wang; Jacques E Nör
Journal:  Cancer Res       Date:  2011-12-08       Impact factor: 12.701

4.  Mathematical model of the effect of intercellular cooperative interactions in cancer during drug therapy.

Authors:  Chanchala D Kaddi; May D Wang
Journal:  Annu ORNL Biomed Sci Eng Cent Conf       Date:  2013-05

5.  Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

Authors:  Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

Review 6.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

7.  CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas.

Authors:  Henning Hanken; Alexander Gröbe; Georg Cachovan; Ralf Smeets; Ronald Simon; Guido Sauter; Max Heiland; Marco Blessmann
Journal:  Clin Oral Investig       Date:  2013-03-15       Impact factor: 3.573

8.  Expression of Bcl-2 and MIB-1 Markers in Oral Squamous Cell Carcinoma (OSCC)- A Comparative Study.

Authors:  Jessica Garewal; Ripin Garewal; Keya Sircar
Journal:  J Clin Diagn Res       Date:  2014-07-20

9.  Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization.

Authors:  En-Hua Xiao; Jing-Qing Li; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

10.  A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Authors:  Paul L Swiecicki; Emily Bellile; Assuntina G Sacco; Alexander T Pearson; Jeremy M G Taylor; Trachette L Jackson; Douglas B Chepeha; Matthew E Spector; Andrew Shuman; Kelly Malloy; Jeffrey Moyer; Erin McKean; Scott McLean; Ammar Sukari; Gregory T Wolf; Avraham Eisbruch; Mark Prince; Carol Bradford; Thomas E Carey; Shaomeng Wang; Jacques E Nör; Francis P Worden
Journal:  Invest New Drugs       Date:  2016-05-26       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.